NANO Nuclear Energy Inc. NANO Nuclear Energy Inc. NANO Nuclear Reports Fiscal Year 2025 Financial Results and Provides Business Update...
Reports
PAPZIMEOS (zopapogene imadenovec-drba) received full approval by the FDA in August PAPZIMEOS launched with a broad label in the US...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025...
Successfully started 204 patients on IBTROZI™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI’s unprecedented...
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Resolute Holdings Management, Inc. (“Resolute Holdings”) (NYSE: RHLD), an operating management company...
Syndax Pharmaceuticals, Inc. – $45.9 million in total revenue, representing 21% growth over 2Q25 – – $32.0 million Revuforj® (revumenib)...
